Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of ALKS 2680 in idiopathic hypersomnia
NL-OMON59666Phase 2Completed
- Sponsor
- Alkermes
- Start
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of alixorexton in hypersomnolence disorder, sponsored by Alkermes. Primary endpoint: Change in Epworth Sleepiness Scale. Started Aug 2025; status: completed.
02
Drugs
alixorexton
03
Conditions
hypersomnolence disorder
Beyond the preview
Go deeper on NL-OMON59666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59666.